Long COVID: Biomarker and Therapeutic Discovery

Share post on social media:
Long COVID: Biomarker and Therapeutic Discovery

SEND ME A PHYSICAL COPY OF CAYMAN CURRENT ISSUE 35

COVID-19 symptoms can persist in an estimated 10% of patients long past recovering from the worst impacts of acute infection and testing negative for SARS-CoV-2. Inconsistencies in symptoms, patient phenotypes, and risk factors make it difficult to pinpoint the exact cause of Long COVID. In this issue of Cayman Currents, explore prominent theories of underlying pathophysiology, lessons from other post-viral syndromes, and Cayman’s products and services to accelerate Long COVID research.

Article:

DOWNLOAD THE INFOGRAPHIC

Request your physical copy here

Cayman CurrentSEND ME A PHYSICAL COPY OF CAYMAN CURRENT ISSUE 35

You might also like...

View blog
New Supplier: DIMA Biotech
1 min read
New Supplier: DIMA Biotech
DIMA Biotechnology LLC. is a top biotech company specializing in preclinical research and development solutions for the Biopharma industry....
New Antibodies Released from DBS
4 min read
New Antibodies Released from DBS
Diagnostic BioSystems is very excited to announce the release of three new primary antibodies specially effective in Bladder Cancer...
The Netherlands buy one million Wantai serological immune tests on corona antibodies in blood:
1 min read
The Netherlands buy one million Wantai serological immune tests on corona antibodies in blood: "Helps to find a way out of lockdown"